Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Elos Medtech AB specializes in the design and manufacturing of medical devices and components, primarily serving the orthopedic and dental markets. The company differentiates itself through its advanced manufacturing capabilities and a strong focus on innovation, particularly in the Nordic region and North America.
Elos Medtech generates revenue by providing high-quality, custom medical devices and components to healthcare providers and manufacturers. Its competitive advantages include a robust R&D pipeline, established relationships with key clients, and a reputation for precision manufacturing, which allows for premium pricing.
Regulatory approvals for new medical devices
Trends in orthopedic and dental surgery volumes
Partnerships with major healthcare providers
Advancements in manufacturing technology
Technological disruption from new materials or manufacturing processes
Regulatory changes affecting medical device approvals
Emergence of low-cost competitors in the medical device space
Potential consolidation among healthcare providers reducing demand for custom solutions
Limited liquidity due to negative free cash flow
Potential pension obligations if applicable
moderate - The demand for medical instruments is somewhat insulated from economic downturns, but overall healthcare spending can be influenced by GDP growth.
Low - The company has no debt, so rising interest rates do not significantly impact financing costs, but they may affect overall healthcare spending and investment.
minimal - Elos Medtech operates with a debt-free balance sheet, reducing vulnerability to credit market fluctuations.
growth - Investors are likely drawn to Elos Medtech's potential for innovation and market expansion in the healthcare sector.
moderate - The stock has shown volatility, particularly with a recent 1-year return of -29.8%, indicating sensitivity to market conditions.